Richard Jund

Title: Richard Jund: Innovator in Therapeutic Biotechnology

Introduction

Richard Jund is a notable inventor based in Strasbourg, France. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic applications. With a total of four patents to his name, Jund's work focuses on innovative solutions for treating proliferative and infectious diseases.

Latest Patents

One of Richard Jund's latest patents involves a mutant having uracil phosphoribosyl transferase (UPRTase) activity. This invention concerns a polypeptide that exhibits UPRTase activity through the mutation of one or several residues of the UPRTase. The patent also includes a nucleotide sequence coding for the UPRTase mutant, a vector for expressing the mutant, a viral particle, a host cell, and a composition containing these elements. Furthermore, the invention outlines their therapeutic use and a treatment method utilizing them. This innovation is particularly valuable in the context of therapy by suicide genes, aimed at treating various proliferative and infectious diseases.

Career Highlights

Richard Jund is currently associated with Transgene S.A., a company that specializes in developing innovative immunotherapies for cancer and infectious diseases. His work at Transgene has allowed him to explore and expand the potential of his inventions in real-world applications.

Collaborations

Richard Jund collaborates with Philippe Erbs, contributing to the advancement of their shared goals in biotechnology and therapeutic innovations.

Conclusion

Richard Jund's contributions to the field of biotechnology through his patents and work at Transgene S.A. highlight his role as an influential inventor. His innovative approaches to therapeutic applications continue to pave the way for advancements in treating complex diseases.